Is Stryker Stock Underperforming the Nasdaq?

Stryker Corporation (SYK) is a global medical technology company with a market capitalization of $126.8 billion. The Portage, Michigan-based company develops and sells innovative products and services across orthopaedics, MedSurg, and neurotechnology, helping healthcare providers improve patient outcomes through surgical equipment, implants, and other medical solutions.

Companies worth $10 billion to $200 billion are generally described as “large-cap stocks,” and SYK definitely fits that description, with its market cap exceeding this threshold and reflecting its substantial size, influence, and position within the Medical Devices industry. Its leadership stems through its strong position in medical technology, global presence, and focus on innovation. Its extensive product portfolio, advanced robotic technologies, strong financial performance, and strategic acquisitions help expand its market reach, strengthen its competitive position, and support long-term growth.

Despite its notable strengths, SYK has slipped 18.4% from its 52-week high of $396.86, reached on September 4, 2025. Over the past three months, SYK stock has climbed 6.1%, outperforming the Nasdaq Composite ($NASX), which declined 2.2% during the same period.

Shares of SYK have declined 7.9% year-to-date and 16.9% over the past 52 weeks, considerably underperforming the NASDAQ Composite’s 13.5% YTD gain and 21.5% return over the past year.

SYK has dipped below both its 50-day and 200-day moving averages in the current month. 

SYK has lagged the broader market partly due to supply chain disruptions and a cybersecurity incident that disrupted manufacturing, resulting in lost sales and elevated backorders. Its weaker-than-expected organic revenue growth and near-term execution concerns have weighed on investor sentiment, despite strong margins and underlying demand. Additionally, valuation compression over the past year has contributed to the stock’s underperformance, even as financial estimates for the company improved.

Adding to that, SYK shares fell about 1.2% on July 30, after reporting its Q2 results. Adjusted EPS of $3.69 surpassed Wall Street expectations of $3.46, while revenue of $6.59 billion exceeded forecasts of $6.56 billion.

In the competitive Medical Devices industry, Abbott Laboratories (ABT) has underperformed SYK, declining 11.9% year-to-date, while slightly outperforming it over the past 52 weeks, with the stock down 16% during the period.

Wall Street analysts are bullish on SYK’s prospects. The stock has a consensus “Strong Buy” rating from the 29 analysts covering it, while the mean price target of $379.81 suggests potential upside of 17.3% from current price levels.